Screener
Immunome IMNM Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of in-process research and development assets | (9,014) | (6,246) |
| Purchases of property and equipment | (3,002) | (3,665) |
| Maturities of marketable securities | — | 15,000 |
| Net cash (used in) provided by investing activities | (12,016) | 5,089 |
| Cash flows from financing activities: | ||
| Proceeds from public offerings | — | 172,500 |
| Payment of offering costs | (364) | (10,485) |
| Proceeds from exercise of stock options | 229 | 213 |
Item 1. Financial Statements.
FAQ
- What is Immunome's investing cash flow?
- Immunome (IMNM) reported investing cash flow of -$12.02M in Q1 2026.
- How has Immunome's investing cash flow changed year-over-year?
- Immunome's investing cash flow decreased by 336.1% year-over-year, from $5.09M to -$12.02M.
- What is the long-term trend for Immunome's investing cash flow?
- Over 3 years (2021 to 2025), Immunome's investing cash flow has grown at a 836.1% compound annual growth rate (CAGR), from -$79K to $64.8M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Immunome's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude